April 3 (Reuters) - The U.S. Food and Drug Administration's website showed that two doses of Eli Lilly's weight-loss drug, Zepbound, would be available only in limited amounts through end of April 2024 due to increased demand. (Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
Pre-market 05:04:35 pm | |||
787 USD | +3.02% | 786.4 | -0.08% |
01:35pm | Eli Lilly Says Once-Weekly Insulin Meets Key Goal in Two Studies | DJ |
09:25am | Roche shares gain on obesity drug results from early-stage trial | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.01% | 709B | |
+31.16% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.55% | 239B | |
+9.40% | 211B | |
-4.13% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Some doses of Lilly's Zepbound in limited availability, US FDA says